MedTrace Logo

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

NCT00229658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1297

Last updated 2015-03-25

Study results available
· View outcomes & findings →

Summary

This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.

Conditions

Interventions

DRUG

pramlintide acetate

Subcutaneous injection prior to each major meal

Sponsors & Collaborators

Principal Investigators

  • Vice President, Medical Development, MD · Amylin Pharmaceuticals, LLC.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00229658 on ClinicalTrials.gov